Controlled Release Carbamazepine: Cognitive Side Effects in Patients with Epilepsy

Abstract

The treatment of epilepsy with carbamazepine (CBZ) may be hampered by cognitive side effects. These side effects are thought to be related to pharmacokinetic properties of the drug. The serum concentration of CBZ is characterized by rapid absorption and a short half-life, which may lead to a considerable fluctuation of the level between doses. Cognitive defects may result from peak levels: short periods with high serum concentration. In a single-blind crossover design, cognitive performance was compared in three conditions. All patients were first tested in the steady state of conventional CBZ. The patients were then assigned randomly to either CBZ-controlled release (CR) or a condition in which conventional CBZ was administered in the same tablet form and dose frequency as CR. Psychological tests were administered four times daily, immediately after the serum samples were taken. A nonmedication control group was tested following the same test scheme to obtain standards for the evaluation of changes in performance during the day. A systematic tendency was found toward higher test performance in the CR condition. This is especially evident for tests of memory and accuracy of visual information processing. The results of the repeated test procedure show that the smoothing effect of the CR condition on serum concentration fluctuations results in a more stable pattern of cognitive functioning during the day.

Neuropsychological Outcomes in Randomized Controlled Trials of Antiepileptic Drugs: A Systematic Review of Methodology and Reporting Standards

“…Most studies proved extremely poor at detailing the procedure involved; in fact, with the exception of Aman et al ( I 9) and Aldenkamp et al (20), no report addressed or mentioned all of these potentially confounding variables.…”

“…In view of this, to find small drug effects, we should use the more highly timed measures. Only three of 47 RCTs (19,20,41), however, included automated tests in the cognitive assessment of AEDs.…”

Once‐Daily Versus Twice‐Daily Vigabatrin: Is There a Difference? The Results of a Double‐Blind Pilot Study

“…An example of this is seen with CBZ, which was associated by some workers (9) with negative effects on cognition only during those periods of peak plasma drug concentration.…”

Alteration of Neurobehavioural Activities by Carbamazepine, Phenytoin and Their Combination in Wistar Rats: A Mini Review

“…Controlled-release medication may be most beneficial in memory and visual information processing (Kalvia et al, 1995). Despite these encouraging findings, some investigators suggested that carbamazepine is more likely to lead to cognitive deterioration than improvement (Aldenkamp et al, 1987). Factors that may be related to a greater incidence of cognitive effects include higher dose (Hemsteadter & Witt 2010) longer duration of intake (Shehata et al 2009) and polytherapy (Bourgeosis, 2004).…”